E. M. Basch
American Society of Clinical Oncology
6 Papers
159 Citations
E. M. Basch is an academic researcher from American Society of Clinical Oncology. The author has contributed to research in topics: Prostate cancer & Population. The author has an hindex of 4, co-authored 6 publications. Previous affiliations of E. M. Basch include Oregon Health & Science University & Memorial Sloan Kettering Cancer Center.
Chat about Author
Papers
American Society of Clinical Oncology endorsement of the Cancer Care Ontario practice Guideline on Nonhormonal Therapy for Men with Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer
E. M. Basch,Mark R. Somerfield,Tomasz M. Beer,Michael A. Carducci,Celestia S. Higano,Maha Hussain,Howard I. Scher +6 more
TL;DR: The review panel agreed with the recommendations as stated in the CCO guideline, with the following qualifications: two of the ASCO content reviewers noted the importance of considering other, nonhormonal therapies in this context that are beyond the scope of this guideline.
80
Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study.
Christopher J. Logothetis,J.S. de Bono,Ana M. Molina,E. M. Basch,Karim Fizazi,Scott North,Kim N. Chi,Robert Jones,Oscar B. Goodman,Paul N. Mainwaring,Cora N. Sternberg,Dennis D. Gagnon,R. Dhawan,Margaret Rothman,Yanni Hao,Cameron S. Liu,T. Kheoh,Howard I. Scher,C. M. Haqq +18 more
TL;DR: Therapy with AA + P offers significant clinical benefits, incl.
33
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research
Michael J. Morris,Michael J. Morris,E. M. Basch,E. M. Basch,George Wilding,Maha Hussain,Michael A. Carducci,Celestia S. Higano,Philip W. Kantoff,William Oh,Eric J. Small,Daniel J. George,Paul Mathew,Tomasz M. Beer,Susan F. Slovin,Susan F. Slovin,Charles J. Ryan,Christopher J. Logothetis,Howard I. Scher,Howard I. Scher +19 more
TL;DR: The PCCTC fulfills a congressional directive to create a clinical trials instrument dedicated to early-phase prostate cancer studies and has built an administrative, informatics, legal, financial, statistical, and scientific infrastructure to support this endeavor.
31
Prostate-Specific Antigen Test for Prostate Cancer Screening: American Society of Clinical Oncology Provisional Clinical Opinion
Robert K. Nam,Thomas K. Oliver,Andrew J. Vickers,Ian M. Thompson,Philip W. Kantoff,Howard L. Parnes,Andrew Loblaw,Bruce J. Roth,James Williams,Sarah Temin,E. M. Basch +10 more
TL;DR: ASO's PSA Testing Expert Panel based their recommendations on a systematic review of recent evidence on the benefits and harms of PSA-based screening on the basis of well-known limitations associated with the randomized trials.
ORIGINAL RESEARCH ARTICLES The Brief Pain Inventory and Its "Pain At Its Worst in the Last 24 Hours" Item: Clinical Trial
Thomas M. Atkinson,Tito R. Mendoza,Steven D. Passik,Howard I. Scher,Charles S. Cleeland,E. M. Basch +5 more
- 01 Jan 2010
TL;DR: It is concluded that the Brief Pain Inventory and its "pain at its worst in the last 24 hours" item generically satisfy most key rec- ommendations outlined in the draft guidance for assessing a pain-reduction treatment effect.
4